Following its initial approval at 150 mg, trastuzumab-strf has also been approved at 420 mg for the treatment of several HER2 ...
BASKING RIDGE, N.J. & RAHWAY, N.J.--(BUSINESS WIRE)--The HERTHENA-Lung02 phase 3 trial evaluating patritumab deruxtecan in patients with locally advanced or metastatic EGFR-mutated non-small cell ...
(RTTNews) - Merck & Co Inc. (MRK) on Tuesday said HERTHENA-Lung02 phase 3 study evaluating Daiichi Sankyo and Merck's patritumab deruxtecan in patients with EGFR-mutated non-small cell lung cancer ...
Health and Me on MSN6d
GST Slashed On Three Cancer Drug: Here's How It Will Affect PatientsThe recent GST cut on cancer drugs could mean significant cost reductions for cancer treatment in India. Read to know how it ...
The trial compared the ADC patritumab deruxtecan to chemotherapy in people with metastatic or locally advanced EGFR-mutated non-small cell lung cancer (NSCLC) after the failure of a third ...
KENILWORTH (NJ) (dpa-AFX) - Merck & Co Inc. (MRK) on Tuesday said HERTHENA-Lung02 phase 3 study evaluating Daiichi Sankyo and Merck's patritumab deruxtecan in patients with EGFR-mutated non-small ...
Seagen won a lawsuit in April 2022 which claimed that Enhertu (trastuzumab deruxtecan) infringes a patient it holds (No. 10,808,039) covering antibody-drug conjugates that include auristatin ...
The results suggest that AZ and Daiichi Sankyo could be in line for a second big win for a cancer ADC to follow Enhertu (trastuzumab deruxtecan), their HER2-directed drug which has just claimed a ...
Die Abnehmmedikamente, die eigentlich für die Behandlung von Adipositas zugelassen sind, werden zunehmend von Menschen mit leichtem Übergewicht nachgefragt. Das führt immer wieder zu Engpässen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback